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Objective: Cyclophosphamide has a role of decreasing high-sensitivity C-reactive protein in the treatment of au-
toimmune disorders. The effect of cyclophosphasmide on high-sensitivity C-reactive protein was investigated in
myocardial ischemia/reperfusion rat.
Methods: Open-chest rats were submitted to 30 minutes of ischemia and followed for 3, 12, or 24 hours of re-
perfusion. All 72 rats survived and were divided into sham, ischemia/reperfusion (I/R) and cyclophosphamide
groups, and each group included 3 time-point subgroups (3, 12, and 24 hours; n ¼ 8 for each subgroup). Cyclo-
phosphamide (0.75 g/m2) or saline was intraperitoneally administrated in the cyclophosphamide or I/R group. A
polyethylene tube was inserted into the left ventricular cavity to detect left ventricular systolic pressure, left ven-
tricular end-diastolic pressure, and maximum rate of rise or fall of left ventricular pressure. In the end, blood was
collected for detection of high-sensitivity C-reactive protein, and hearts were harvested for histopathologic assess-
ment and infarct size determination.
Results:Compared with the I/R group, rats treated with cyclophosphamide showed a significant recovery in myo-
cardial function with improved left ventricular systolic pressure (88.27 3.78 vs 68.62 3.78 mmHg at 3 hours,
92.04 3.77 vs 63.74 4.87 mmHg at 12 hours, and 90.41 3.98 vs 64.21 4.88 mmHg at 24 hours; P<.05,
respectively). Left ventricular end-diastolic pressure and maximum rate of rise or fall of left ventricular pressure
also had similar trends. Infarct size was reduced (26.1% 0.4% vs 40.4% 0.4% at 3 hours, 21.6% 0.4% vs
49.9%  0.4% at 12 hours, and 21.6%  0.4% vs 40.0%  0.4% at 24 hours; P< .01, respectively). Histo-
pathologic damage score was attenuated (1.83 0.14 vs 2.17 0.14 at 3 hours, 2.33 0.14 vs 3.17 0.14 at 12
hours, and 2.83 0.14 vs 3.83 0.14 at 24 hours; P<.01, respectively). Plasma high-sensitivity C-reactive pro-
tein concentration was significantly reduced (29.28  0.51 vs 32.26  0.51 ng/mL at 3 hours, 29.06  0.50 vs
31.8  0.51 ng/mL at 12 hours, and 28.61  0.51 vs 31.86  0.51 ng/mL at 24 h; P< .01, respectively).
Conclusion: Cyclophosphamide protects myocardial ischemia/reperfusion injury in the rat with a decrease in
plasma concentration of high-sensitivity C-reactive protein.
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SCyclophosphamide has been used in the treatment of auto-
immune disorders.1 An early decrease in C-reactive protein
(CRP) concentration was found in patients with autoimmune
disease after treatment with intravenous cyclophospha-
mide.2 High-sensitivity C-reactive protein (hs-CRP) is part
of the nonspecific acute-phase response protein and is one
of the most sensitive markers3 of systemic inflammation
and tissue damage, along with acute myocardial infarction
and ischemia/reperfusion (I/R) injury.4,5 We hypothesized
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with cyclophosphamide treatment by decreasing hs-CRP
in the rat.
MATERIALS AND METHODS
The Animal Care and Use Committee of Zhejiang University approved
all procedures, and the investigation conformed to the ‘‘Guidelines for
the Care and Use of Laboratory Animals,’’ which was published by the
National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Animal Model
We used 70% povidone–iodine to sterilize the skin and an autoclave to
sterilize surgical instruments and drapes by high pressure/high temperature
steam; 2% glutaraldehyde was used for surgical scrub. We wore sterile
gloves and a surgical mask, then disinfected the operating table before sur-
gery. Adult male Sprague–Dawley rats (250–275 g, provided by Shanghai
Laboratory Animal Center, Chinese Academy of Sciences) were anesthe-
tized with chloral hydrate (400 mg/kg) through an intraperitoneal injection.
The animals were placed in a supine position with their paws and upper cen-
tral incisors taped to the operating table. An endotracheal tube was inserted
through the mouth into the trachea. Artificial respiration was maintained
through the respirator with an inspiratory/expiratory ratio of 1:2, a frequency
of 65 strokes/min, and a tidal volume of 15 mL to maintain normal arterial
oxygen tension, carbon dioxide tension, and pH. We clipped the hair withardiovascular Surgery c Volume 137, Number 4 991




CRP ¼ C-reactive protein
dp/dtmax ¼ maximum rate of rise or fall of left
ventricular pressure
hs-CRP ¼ high-sensitivity C-reactive protein
I/R ¼ ischemia/reperfusion
LVEDP ¼ left ventricular end-diastolic pressure
LVSP ¼ left ventricular systolic pressure
a No. 40 clipper blade and disinfected the skin. We draped the animal with
sterile drapes to avoid contamination of the incision and exposed the surgi-
cal field. Themiddle skin incisionwas extended from the sternal angle down
to the xiphoid. The left pectoral muscles were dissected longitudinally to ex-
pose the left third and fourth ribs. A parasternal incision was made to open
the chest by dissecting the intercostal muscles between the left third and
fourth ribs and kept open by a stent without cutting the ribs. A 7–0 silk su-
ture was passed underneath the left anterior descending coronary artery (2–3
mm inferior to the left auricle) with an occluder fixed onto the left anterior
descending coronary artery and tied. Coronary artery ligation was achieved
and reperfusion was induced by releasing the tie. Significant electrocardio-
graphic changes, including widening of the QRS complex and elevation of
the ST segment, and color changes of the area at risk were considered indic-
ative of successful coronary occlusion and reperfusion. Warmed saline so-
lution (1 mL) was administered intraperitoneally in case of dehydration after
the operation. The chest was closed in layers, and the animal was weaned
from the respirator when spontaneous breathing began.6 The rat was placed
back in a separate sterile pack for no more than 5 animals.
Experimental Protocol
Rats were subjected to 0.75 g/m2 cyclophosphamide7 (Jiangsu Hengrui
Medicine Co Ltd, NanJing, China) or saline through intraperitoneal injec-
tion before surgery (about 10–20 minutes), followed by 30 minutes of left
ventricular normothermic ischemia and 3, 12, or 24 hours of reperfusion
in the cyclophosphamide group or I/R group (n ¼ 8 in each subgroup).
The dose of cyclophosphamide that we selected was about 20% higher
than the commonly used dose in studies of patients with rheumatoid arthritis
or systemic vasculitis but still within the safe range, for rats tolerate a higher
dosage than human beings. Furthermore, the present dose had been shown
to be effective and widely used in rat experiments.7 In the sham group, sa-
line was intraperitoneally injected before the operation. The silk suture
crossed without ligation and the rat did not receive I/R. In the I/R group, sa-
line was intraperitoneally injected before operation, and the rat received I/R.
In the cyclophosphamide group, cyclophosphamide was intraperitoneally
injected before the operation, and the rat received I/R. Hemodynamic pa-
rameters were detected at 0, 3, 12, and 24 hours after reperfusion. Blood
was collected for hs-CRP detection, and hearts were harvested for histopath-ologic assessment and infarct size determination at the end of reperfusion
(Figure 1).
Hemodynamic Assessment
At the end of reperfusion, rats were anesthetized again, and a polyethyl-
ene tube (PE 50; Becton Dickinson Co, Franklin Lakes, NJ) was inserted
into the left ventricular cavity via the right common carotid artery.8 The
pressure was transduced and monitored by a pressure transducer (Xing-
HangXinYe Co Ltd, Beijing, China). Left ventricular systolic pressure
(LVSP), end-diastolic pressure (LVEDP) and maximum rate of pressure
rise or fall (dp/dtmax) were recorded and programmed by using a biotic
signal collection and processing system (MedLab-U/4cs, MeiYi Co Ltd,
Nanjing, China).
Assessment of Risk Area and Infarct Size
After hemodynamic parameters had been recorded, the chest was reop-
ened under artificial respiration. The coronary artery was briefly occluded
again through ligation of the tie that remained at the site of the previous oc-
clusion. Immediately, 2 mL of Evans blue solution (1%) was infused
through the catheter into the beating left ventricular cavity to delineate the
ischemic area. After removal of the right ventricle and atria, the left ventricle
was cross-sectioned from the apex to the atrioventricular groove into 7 spec-
imens about 1.5 mm in thickness with a steric heart mould.6 These slices
were incubated with 2% triphenyltetrazolium chloride solution (pH ¼
7.4) for 15 to 20minutes at 37C in a dark room. Then the slices were photo-
graphed and the image was programmed by the analysis software (Image J
1.36; Macintosh, National Institute of Mental Health). The risk area was de-
termined by the percentage of the left ventricle unstained by Evans blue dye,
and the infarct area was determined by the percentage of triphenyltetrazo-
lium chloride–unstained area to Evans blue–unstained area.6
Histopathologic Analysis
Additional hearts were fixed in 10% formalin and embedded in paraffin.
The paraffin-embedded tissues were sectioned and stained with hematoxy-
lin and eosin and analyzed by light microscopy. An observer blinded to the
treatment regimen examined the sections for histopathologic injury from 6
random high-power fields.9 The following morphologic criteria10 were used
to determine the histopathologic damage: score 0 ¼ no damage; score 1
(mild) ¼ interstitial edema and focal necrosis; score 2 (moderate)¼ diffuse
myocardial cell swelling and necrosis; score 3 (severe) ¼ necrosis with the
presence of contraction bands, neutrophil infiltration, and capillary com-
pression; and score 4 (highly severe) ¼ widespread necrosis with the pres-
ence of contraction bands, neutrophil infiltration, capillary compression,
and hemorrhage.
HS-CRP Measurement
Measurements of hs-CRP were performed by the rat hs-CRP enzyme-
linked immunosorbent assay kit (RapidBio Lab. Calabasas, Calif) that has
been used in a variety of studies. The lowest limit of detection is 0.1 ng/mL.FIGURE 1. Experimental protocol. I/R, Ischemia/reperfusion; CP, cyclophosphamide.
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Wang et al Cardiopulmonary SupportTABLE 1. LVSP, LVEDP,þdp/dtmax, anddp/dtmax in different treatment groups
Groups LVSP (mm Hg) LVEDP (mm Hg) þdp/dtmax (mm Hg/s) dp/dtmax (mm Hg/s)
Sham group (n ¼ 8 in each subgroup)
0 h 109.97  5.34 2.16  0.31 6876.94  484.22 7144.32  742.12
3 h 104.23  5.34 2.47  0.32 6723.68  484.22 5945.40  742.11
12 h 107.69  5.34 2.62  0.34 6820.49  484.22 7254.33  742.12
24 h 106.35  5.34 2.57  0.34 6705.73  484.22 5989.14  742.12
I/R group (n ¼ 8 in each subgroup)
0 h 88.07  4.88 14.10  0.78* 5690.86  442.03 4655.37  677.46
3 h 68.62  3.78*z 14.45  0.48* 3476.99  342.40*z 2054.12  524.76*
12 h 63.74  4.87* 15.13  0.88* 5182.68  442.03* 4070.54  677.46*
24 h 64.21  4.88* 15.50  0.81* 3608.68  326.46* 3032.02  500.33*
Cyclophosphamide group (n ¼ 8 in each subgroup)
0 h 93.44  4.22 14.22  0.61* 5533.62  382.81 4603.57  586.70
3 h 88.27  3.78*y 14.57  0.94* 4675.78  342.40*y 4123.71  524.76*
12 h 92.04  3.77*y 13.00  0.88*y 5094.34  342.39* 5431.13  524.76*
24 h 90.41  3.98*y 13.24  0.79*y 4992.57  300.30*y 3828.05  460.24*
Expressed as mean SEM. *P<.01 compared with sham group of the same time-point. yP<.05 compared with I/R group of the same time-point. zP<.05 compared with 0h in I/R
group.Statistical Analysis
All data were expressed as mean SEM. Analyses were carried out with
the SPSS statistical package (version 13.0; SPSS, Inc, Chicago, Ill). Differ-
ences between specific means were tested by univariate analysis using
general linear models (GLM procedure for SPSS) to perform a 2-factor
(or 2-way) analysis of variance.
RESULTS
Eighty-four rats were subjected to surgery, and the surviv-
ing 72 rats were assigned to 3 groups: sham group, I/R group,
and cyclophosphamide group. Three rats died during anesthe-
sia, 5 rats died during surgery (3 in the I/R group, and 2 in the
cyclophosphamide group), and 4 rats died after surgery (2 in
the I/R group, and 2 in the cyclophosphamide group). The sur-
gical technique used in this study significantly reduced early
mortality and also reduced the variation in risk area.
Improved Myocardial Function in
Cyclophosphamide Group (Table 1)
Damaged LVSP, LVEDP anddp/dtmax were recorded in
the I/R and cyclophosphamide groups and compared withthe sham group. LVSP, LVEDP, and dp/dtmax became
worse at 24 hours in the I/R group, but treatment with cyclo-
phosphamide generated a significant improvement in car-
diac function at all time points.
Decrease in Myocardial Infarct Size in
Cyclophosphamide Group (Table 2, Figure 2)
Similarly sized risk areas were observed in both the I/R
and cyclophosphamide groups at each time point. The in-
farct size was reduced (P< .01, respectively) by 14.28%
at 3 hours, 28.34% at 12 hours, and 18.40% at 24 hours
in the group of rats treated with cyclophosphamide com-
pared with the I/R group.
Attenuated Histopathologic Damage in Myocytes
(Table 2, Figure 3)
Three hours after transient I/R, myocardial destruction
with focal infiltration of polymorphonuclear neutrophils
was evident in the left ventricular free wall. Myocardial
damage rapidly progressed after reperfusion, and pathologicC
P
STABLE 2. Risk area, infarct size, damage score, and Hs-CRP concentration in different treatment groups
Groups Risk area (%) Infarct size (%) Damage score Hs-CRP (ng/mL)
Sham group (n ¼ 8 in each subgroup)
3 h 0 0 0 11.90  0.54
12 h 0 0 0 12.13  0.51
24 h 0 0 0 11.67  0.51
I/R group (n ¼ 8 in each subgroup)
3 h 41.4  0.6 40.4  0.4 2.17  0.14 32.26  0.51
12 h 41.3  0.6 49.9  0.4 3.17  0.14 31.80  0.51
24 h 40.9  0.6 40.0  0.4 3.83  0.14 31.86  0.51
Cyclophosphamide group (n ¼ 8 in each subgroup)
3 h 40.5  0.6 26.1  0.4 1.83  0.14* 29.28  0.51*
12 h 41.0  0.6 21.6  0.4 2.33  0.14* 29.06  0.50*
24 h 40.7  0.6 21.6  0.4 2.83  0.14* 28.61  0.51*
Expressed as mean  SEM. *P< .01 compared with I/R group of the same time point.
The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 4 993
Cardiopulmonary Support Wang et al
C
P
SFIGURE 2. Images of infarct area: A, Twelve hours in the ischemia/reperfusion group. B, Twelve hours in the cyclophosphamide group. C, Risk area is
expressed as the percentage of Evans blue–unstained area to the whole left ventricular area. D, Infarct size is expressed as the percentage of triphenyltetra-
zolium chloride–unstained area to Evans blue–unstained area. I/R, Ischemia/reperfusion; CP, cyclophosphamide. *P< .01 compared with I/R group at the
same time point.features of the infarct area became apparent by 24 hours after
reperfusion with widespread necrosis, the presence of con-
traction bands, polymorphonuclear neutrophil infiltration,
capillary compression, and hemorrhage. In the group with
cyclophosphamide treatment, the histologic features were
close to normal cardiac structure or mild architectural dam-
age, characterized by interstitial edema and localized ne-
crotic areas. The damage score was reduced in the group
of rats treated with cyclophosphamide compared with the
control group (P< .01) at 3, 12, and 24 hours.
Concentration of HS-CRP (Table 2)
Hs-CRP was elevated pronouncedly after reperfusion. In-
asmuch as it well represents the increased infarct size and
mortality rate of rats, it can be used as a marker of the sever-
ity of myocardial injury in myocardial infarction.11-13 The994 The Journal of Thoracic and Cardiovascular Surlevels of hs-CRP were decreased after cyclophosphamide
administration at the 3 time points (P< .01).
DISCUSSION
Our study discovered the novel cardiac protective effect
of cyclophosphamide in the rat subjected to I/R. A burst of
hs-CRP elevation in plasma was detected after I/R. Cyclo-
phosphamide significantly prevented the secretion of hs-
CRP. Of interest, these cyclophosphamide-treated rats
were associated with reduced infarct size, histopathologic
damage score, and preserved myocardial function. The find-
ings are consistent with the notion that activation of hs-CRP
might play a role in I/R injury. Furthermore, our data for the
first time suggest that cyclophosphamide might mitigate
myocardial injury partially by its anti-inflammation effect
of hs-CRP downregulation.gery c April 2009
Wang et al Cardiopulmonary SupportFIGURE 3. Hematoxylin-eosin–stained left ventricular sections from rats treated with cyclophsphamide or saline. Magnification for all images: 4003. A,
HE-stained section at 3 hours in I/R group. B, HE-stained section at 3 hours in cyclophosphamide group. C, HE-stained section at 12 hours in I/R group. D,
HE-stained section at 12 hours in cyclophosphamide group. E, HE-stained section at 24 hours in I/R group. F, HE-stained section at 24 hours in cyclophos-
phamide group. G, Damage score. I/R, Ischemia/reperfusion, CP, cyclophosphamide. *P< .01 compared with I/R group at the same time point; #P< .01
among different time points in I/R groups.
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SA previous study had shown hs-CRP elevation after I/R
injury, which is significantly elevated by 54% 2 hours after
reperfusion and more pronounced (82% increase) 24 hours
after I/R injury.14 Such a pathologic state seems to closely
resemble the pathophysiology in autoimmune diseases, in
which cyclophosphamide is often used as a tool for decreas-
ing CRP. The introduction of cyclophosphamide has radi-
cally improved survival in autoimmune diseases.15,16 In
this regard, the study suggests the possible use of cyclophos-
phamide as additional therapeutic treatment in myocardial
I/R injury.
For many years, hs-CRP has been known as a typical
systemic inflammation protein during myocardial I/R in-
jury.11-13 Many studies suggest that CRP is not only a sen-
sible inflammatory marker, but also should be considered
as a direct inflammatory promoter11-13 that binds to the
damaged myocardial cells, finally increases the infarct
size, and worsens the overall postinfarct outcomes.
Hack,12 Beranek,13 and their associates have lately intro-
duced a concept, highlighting the potential pathogenetic
importance of CRP binding to nonirremediably damaged
cells leading to tissue damage. These works and our pres-
ent study could suggest that patients with elevated CRP
might benefit from anti-inflammatory therapy in myocar-
dial I/R injury. Certain medications might be helpful in
some patients before a procedure such as percutaneous
coronary intervention is performed. There are some medi-
cations that may help to decrease hs-CRP. At present, only
statins and aspirin have been found to have an effect on
decreasing hs-CRP levels.17,18 The general anti-inflamma-
tory agent aspirin is already used routinely in patients with
coronary disease, and statins have been widely used as
well. The anti-inflammatory activity of cyclophosphamide
could give the drug a potential benefit in preventing myo-
cardial I/R injury.
Inevitably, possible toxic side effects of cyclophospha-
mide may limit its clinical application in many diseases.
As side effects are usually seen at high doses, cyclophospha-
mide is a relatively safe drug at low doses. Previous reports
have suggested that cyclophosphamide could cause myelo-
suppression19,20 after flushing dose injection during antican-
cer treatment. Currently, we choose a much lower dose of
cyclophosphamide7 compared with that in anticancer treat-
ment. At this dose level, it should not cause serious side
effects.1,2 Itescu and associates21 have applied cyclophos-
phamide pulse therapy in sensitized cardiac allograft recipi-
ents, and it proved to be safe and highly effective.
CONCLUSIONS
Our results demonstrate that cyclophosphamide could
mitigate myocardial I/R injury in the rat with a decrease in
plasma concentration of hs-CRP. These findings could sug-996 The Journal of Thoracic and Cardiovascular Surggest a therapeutic benefit by giving anti-inflammatory med-
ication in the setting of myocardial I/R injury.
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